Bottom line
XLV vs PJP: the short answer
XLV (State Street(R) Health Care Select Sector SPDR(R) ETF) and PJP (Invesco Pharmaceuticals ETF) are quite different portfolios: only about 38% of their top holdings (by weight) are shared.
XLV is cheaper at 0.08% vs 0.58% — a difference of $50 a year per $10,000 invested.
Over five years, PJP returned +9.0% a year vs +8.1% for XLV.
Updated Nov 19, 2026
XLV vs PJP side by side
| XLV | PJP | |
|---|---|---|
| Type | ETF | ETF |
| Fund family | SPDR (State Street) | Invesco |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.08% | 0.58% |
| Annual cost per $10k | $8 | $58 |
| 10-yr cost on $10k (prospectus) | $103 | $726 |
| Max front load | None | None |
| 12b-1 fee | 0.02% | — |
| 1-yr return | +14.5% | +27.9% |
| 5-yr return (annualized) | +8.1% | +9.0% |
| 10-yr return (annualized) | +9.8% | +5.1% |
| Best quarter | +14.5% | +18.1% |
| Worst quarter | −12.7% | −14.8% |
| Net assets (fund) | $40.6B | $472.1M |
| Number of holdings | 65 | 33 |
| Portfolio turnover | 2% | 36% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | XLV | PJP | Difference |
|---|---|---|---|
| 2025 | +14.5% | +27.9% | −13.4% |
| 2024 | +2.5% | +9.7% | −7.2% |
| 2023 | +2.0% | −2.2% | +4.2% |
| 2022 | −2.1% | −2.0% | −0.0% |
| 2021 | +25.9% | +14.5% | +11.5% |
| 2020 | +13.3% | +11.2% | +2.1% |
| 2019 | +20.7% | +4.7% | +16.0% |
| 2018 | +6.3% | −1.7% | +8.0% |
| 2017 | +21.7% | +15.3% | +6.4% |
| 2016 | −2.8% | −19.3% | +16.4% |
Source: Fund prospectus bar charts
Holdings overlap
10 of XLV's top 25 holdings also appear in PJP's top 25.
| Holding | XLV | PJP |
|---|---|---|
| Eli Lilly & Co | 16.51% | 5.02% |
| Johnson & Johnson | 10.64% | 5.18% |
| AbbVie Inc | 7.74% | 5.48% |
| Merck & Co Inc | 5.52% | 5.06% |
| Amgen Inc | 3.40% | 5.33% |
| Abbott Laboratories | 2.75% | 5.67% |
| Gilead Sciences Inc | 2.73% | 4.53% |
| Pfizer Inc | 2.39% | 4.50% |
| Bristol-Myers Squibb Co | 2.05% | 2.94% |
| Regeneron Pharmaceuticals Inc | 1.08% | 3.14% |
Source: SEC Form N-PORT
XLV top 10
- Eli Lilly & Co — 16.51%
- Johnson & Johnson — 10.64%
- AbbVie Inc — 7.74%
- UnitedHealth Group Inc — 6.57%
- Merck & Co Inc — 5.52%
- Amgen Inc — 3.40%
- Thermo Fisher Scientific Inc — 3.24%
- Abbott Laboratories — 2.75%
- Gilead Sciences Inc — 2.73%
- Intuitive Surgical Inc — 2.45%
PJP top 10
- Invesco Private Prime Fund — 7.93%
- Abbott Laboratories — 5.67%
- AbbVie Inc. — 5.48%
- Amgen Inc. — 5.33%
- Johnson & Johnson — 5.18%
- Merck & Co., Inc. — 5.06%
- Eli Lilly and Co. — 5.02%
- Corcept Therapeutics Inc. — 4.96%
- Gilead Sciences, Inc. — 4.53%
- Pfizer Inc. — 4.50%
FAQ
What is the difference between XLV and PJP?
Which is cheaper, XLV or PJP?
Should I own both XLV and PJP?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.